Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd

Link copied
Case Copied 19 min read

FEDERAL COURT OF AUSTRALIA

Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2013] FCA 226

Citation: Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2013] FCA 226
Parties: BAYER PHARMA AKTIENGESELLSCHAFT  and BAYER AUSTRALIA LIMITED ACN 000 138 714 v GENERIC HEALTH PTY LTD  ACN 110 617 859 and LUPIN AUSTRALIA PTY LTD ACN 112 038 105
File number(s): NSD 236 of 2012
Judge: JAGOT J
Date of judgment: 11 March 2013
Catchwords: EVIDENCE – experimental proof of a fact – manufacture of tablets for subsequent tests – party denied opportunity to observe – application for leave – leave refused
Legislation: Evidence Act1995 (Cth)
Federal Court Rules 2011
Cases cited: Lexmark International v Boomerang Imaging Supplies Pty Ltd (2001) 112 FCR 331; [2001] FCA 833
Mölnlycke Health Care AB v Brightwake Limited (2011) FSR 26; [2011] EWHC 140
Date of hearing: 11 March 2013
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 29
Counsel for the First and Second Applicants: D Shavin QC with Helen Rofe
Counsel for the First and Second Respondents: A H Bowne SC with A D B Fox
Solicitor for the First and Second Applicants: Davies Collison Cave Law
Solicitor for the First and Second Respondents: K & L Gates

THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 236 of 2012

BETWEEN:

BAYER PHARMA AKTIENGESELLSCHAFT
First Applicant

BAYER AUSTRALIA LIMITED ACN 000 138 714
Second Applicant

AND:

GENERIC HEALTH PTY LTD  ACN 110 617 859
First Respondent

LUPIN AUSTRALIA PTY LTD ACN 112 038 105
Second Respondent

JUDGE:

JAGOT J

DATE OF ORDER:

11 MARCH 2013

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The interlocutory application filed 5 March 2013 be dismissed.

2.The respondents are to pay the applicants’ costs of the interlocutory application as agreed or taxed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 236 of 2012

BETWEEN:

BAYER PHARMA AKTIENGESELLSCHAFT
First Applicant

BAYER AUSTRALIA LIMITED ACN 000 138 714
Second Applicant

AND:

GENERIC HEALTH PTY LTD  ACN 110 617 859
First Respondent

LUPIN AUSTRALIA PTY LTD ACN 112 038 105
Second Respondent

JUDGE:

JAGOT J

DATE:

11 MARCH 2013

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. This is an interlocutory application filed 5 March 2013 and returnable for hearing this morning, the first day of the hearing of this matter.  The respondents seek leave to rely upon the affidavit of Terence Clive Burgess sworn 27 September 2012 filed in the proceedings as part of the respondents’ evidence in chief on validity.  The interlocutory application was filed in response to the applicants giving the respondents notice that there would be objection taken to Mr Burgess’s affidavit. 

  2. The first issue for determination is whether r 34.50 of the Federal Court Rules 2011 is engaged. That rule provides that if a party proposes to tender as evidence in a proceeding experimental proof of a fact, the proponent…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2013] FCA 226
Decision Date

CaseChat Overview and Summary

Bayer Pharma Aktiengesellschaft (Bayer) brought an action against Generic Health Pty Ltd (Generic Health) in the Federal Court of Australia. Bayer alleged that Generic Health had infringed Bayer's patent for a pharmaceutical product. The crux of the dispute lay in the manufacturing process of the product, specifically the creation of tablets for subsequent testing. Bayer sought to inspect the manufacturing process but was denied access. Bayer then applied for leave to observe the manufacturing process.

The primary legal issue before the Court was whether Bayer should be granted leave to observe the manufacturing process at Generic Health's facility. Bayer argued that such inspection was necessary to gather experimental evidence to support its case. Generic Health, on the other hand, contended that allowing such observation would compromise its intellectual property and commercial interests. The Court had to balance Bayer's right to inspect against Generic Health's rights to protect its confidential information.

The Court held that Bayer's application for leave to observe the manufacturing process was an attempt to obtain evidence by circumventing the standard discovery process. It found that Bayer had not demonstrated that the evidence sought could not be obtained by other means. The Court also noted the significant burden that such an inspection would place on Generic Health, particularly regarding the protection of its intellectual property. Consequently, the Court dismissed Bayer's application for leave and ordered that Generic Health was to pay Bayer's costs of the interlocutory application.

Orders

Orders of the court

1. The interlocutory application filed 5 March 2013 be dismissed.

2. The respondents are to pay the applicants’ costs of the interlocutory application as agreed or taxed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.